Cargando…
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID-19. Here, we report outcomes and risk factors for serious disease in patients with multiple myeloma treated at five large academi...
Autores principales: | Hultcrantz, Malin, Richter, Joshua, Rosenbaum, Cara A., Patel, Dhwani, Smith, Eric L., Korde, Neha, Lu, Sydney X., Mailankody, Sham, Shah, Urvi A., Lesokhin, Alexander M., Hassoun, Hani, Tan, Carlyn, Maura, Francesco, Derkach, Andriy, Diamond, Benjamin, Rossi, Adriana, Pearse, Roger N., Madduri, Deepu, Chari, Ajai, Kaminetzky, David, Braunstein, Marc J., Gordillo, Christian, Reshef, Ran, Taur, Ying, Davies, Faith E., Jagannath, Sundar, Niesvizky, Ruben, Lentzsch, Suzanne, Morgan, Gareth J., Landgren, Ola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668224/ https://www.ncbi.nlm.nih.gov/pubmed/34651141 http://dx.doi.org/10.1158/2643-3230.BCD-20-0102 |
Ejemplares similares
-
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020) -
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021) -
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023) -
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)